Aastrom shares soar after FDA lifts hold

Aastrom Biosciences says that the FDA has removed the clinical hold from its U.S. Phase II IMPACT-DCM clinical trial for congestive heart failure and that patient enrollment would resume at the four initiated clinical sites. The hold was put in place last month after a patient in the study experienced a severe adverse event. Enrollment should be complete by the end of the year now. That news sent Aastrom's shares soaring 69 percent. Aastrom release